dc.contributor.author |
Wudhikarn K. |
|
dc.contributor.author |
Bunworasate U. |
|
dc.contributor.author |
Julamanee J. |
|
dc.contributor.author |
Lekhakula A. |
|
dc.contributor.author |
Ekwattanakit S. |
|
dc.contributor.author |
Khuhapinant A. |
|
dc.contributor.author |
Chuncharunee S. |
|
dc.contributor.author |
Niparuck P. |
|
dc.contributor.author |
Numbenjapon T. |
|
dc.contributor.author |
Prayongratana K. |
|
dc.contributor.author |
Kanitsap N. |
|
dc.contributor.author |
Wongkhantee S. |
|
dc.contributor.author |
Makruasi N. |
|
dc.contributor.author |
Wong P. |
|
dc.contributor.author |
Norasetthada L. |
|
dc.contributor.author |
Nawarawong W. |
|
dc.contributor.author |
Sirijerachai C. |
|
dc.contributor.author |
Chansung K. |
|
dc.contributor.author |
Suwanban T. |
|
dc.contributor.author |
Praditsuktavorn P. |
|
dc.contributor.author |
Intragumtornchai T. |
|
dc.contributor.author |
on behalf of Thai Lymphoma Study Group |
|
dc.date.accessioned |
2021-04-05T03:02:05Z |
|
dc.date.available |
2021-04-05T03:02:05Z |
|
dc.date.issued |
2020 |
|
dc.identifier.issn |
18794068 |
|
dc.identifier.other |
2-s2.0-85063582476 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/12175 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063582476&doi=10.1016%2fj.jgo.2019.03.016&partnerID=40&md5=3ef0840820bce919d55b06f2fc54bb86 |
|
dc.description.abstract |
Introduction: Peripheral T cell NHL (PTCL) and natural killer/T cell NHL (NKTCL) are relatively rare disorders. Data on clinical presentation, treatment and outcome are limited especially in older age groups. Methods: We identified 127 patients with PTCL and NKTCL, excluding cutaneous T/NK cell lymphoma, aged over 60 years old from Thailand nationwide multicenter registry. Results: Of 127 patients, median age of diagnosis was 67 years old. Patients aged older than 75 years old had similar characteristics to younger (60–74 years old) but higher comorbidity index. Seventy-nine patients (62.2%) received intensive/definite multi-agent chemotherapy, however, the proportion was significant lower in older patients (70.4% vs 34.5%, p <. 001). After a median follow up duration of 17.3 months, 2-year progression free survival and overall survival were 38.1% and 48.5%. Univariate and multivariable analysis demonstrated older age, poor performance status and absence of definite multi-agent chemotherapy were associated with inferior survival. Definite multi-agent lymphoma specific chemotherapy was an independent factor for overall survival after adjustment for age, comorbidity index, performance status and prognostic index for T cell lymphoma. Conclusion: Despite overall poor prognosis of PTCL and NKTCL in older adults, chemotherapy could result in objective response and long-term survival in selected patients of this vulnerable age group thus emphasizing the importance of comprehensive geriatric evaluation. © 2019 |
|
dc.subject |
asparaginase |
|
dc.subject |
cyclophosphamide |
|
dc.subject |
dexamethasone |
|
dc.subject |
doxorubicin |
|
dc.subject |
etoposide |
|
dc.subject |
ifosfamide |
|
dc.subject |
methotrexate |
|
dc.subject |
prednisolone |
|
dc.subject |
steroid |
|
dc.subject |
vincristine |
|
dc.subject |
adult |
|
dc.subject |
aged |
|
dc.subject |
aging |
|
dc.subject |
Article |
|
dc.subject |
cancer chemotherapy |
|
dc.subject |
cancer combination chemotherapy |
|
dc.subject |
cancer prognosis |
|
dc.subject |
cancer radiotherapy |
|
dc.subject |
cancer registry |
|
dc.subject |
cohort analysis |
|
dc.subject |
comorbidity |
|
dc.subject |
controlled study |
|
dc.subject |
diarrhea |
|
dc.subject |
drug dose escalation |
|
dc.subject |
drug fatality |
|
dc.subject |
drug safety |
|
dc.subject |
febrile neutropenia |
|
dc.subject |
female |
|
dc.subject |
follow up |
|
dc.subject |
geriatric assessment |
|
dc.subject |
groups by age |
|
dc.subject |
human |
|
dc.subject |
ileus |
|
dc.subject |
infection |
|
dc.subject |
intensive care |
|
dc.subject |
long term survival |
|
dc.subject |
major clinical study |
|
dc.subject |
male |
|
dc.subject |
multiple cycle treatment |
|
dc.subject |
neuropathy |
|
dc.subject |
neutropenia |
|
dc.subject |
NK T cell lymphoma |
|
dc.subject |
nonhodgkin lymphoma |
|
dc.subject |
oral mucositis |
|
dc.subject |
overall survival |
|
dc.subject |
peripheral T cell lymphoma |
|
dc.subject |
physical performance |
|
dc.subject |
polypharmacy |
|
dc.subject |
priority journal |
|
dc.subject |
progression free survival |
|
dc.subject |
Thailand |
|
dc.subject |
thrombocytopenia |
|
dc.subject |
treatment outcome |
|
dc.title |
Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Journal of Geriatric Oncology. Vol 11, No.1 (2020), p.62-68 |
|
dc.identifier.doi |
10.1016/j.jgo.2019.03.016 |
|